Drug Topics - June 16, 2008 - (Page 52)

52 DRUG TOPICS JUNE 16, 2008 www.drugtopics.com TEST QUESTIONS 5. Which of the following is NOT used as part of the 12. Which of the following is true with respect to B- diagnosis process for HF? a. b. c. d. Echocardiogram Pulmonary function tests Patient history Physical assessment blocker use in HF? a. Should be started at target dose and titrated down as needed b. Contraindicated in patients with diabetes c. Requires close monitoring of BP and HR d. Should be avoided in patients with severe HF 13. Which statement accurately reflects the role of 6. A patient with structural heart disease with prior or current symptoms of heart failure would be staged at what level? a. b. c. d. Stage Stage Stage Stage A B C D diuretics in HF? a. Diuretics are used primarily for decreasing fluid and improving symptoms. b. Monotherapy with diuretics should be attempted in Stage A HF patients. c. Thiazide diuretics are the most common class used in HF. d. Diuretics have shown many long-term mortality benefits in numerous trials. 14. Aldosterone receptor antagonists (ARAs): a. Should be started in patients with early symptoms of HF b. Have shown scant mortality benefits in HF trials c. Are safe for use in renal dysfunction d. Require close monitoring of K+ levels 15. Which of the following is NOT TRUE with regards 7. A patient who develops symptoms with less than ordinary exertion would be classified into what NYHA functional category? a. b. c. d. Class Class Class Class I II III IV 8. Which of the following is NOT a defined goal of chronic HF therapy? a. Decrease rate of hospitalizations b. Enroll all patients in multi-disciplinary HF clinic c. Decrease patient symptoms and improve quality of life d. Prevent and/or slow progression of the disease 9. Which of the following is correct with ACE inhibi- to digoxin therapy in HF? a. Has a narrow therapeutic index b. Is linked to multiple drug interactions c. Requires close monitoring for toxic adverse effects d. Has been shown to decrease both morbidity and mortality in HF 16. The use of hydralazine/isosorbide dinitrate has tor use in heart failure? a. Recommended for patients intolerant to betablocker therapy b. Have only been studied in few clinical trials c. Should be used as monotherapy in most HF patients d. Was first drug class to show mortality benefits in HF 10. Which of the following adverse effects seen with shown benefits in HF for which of the following reasons? a. Increases compliance due to once-daily dosing b. Decreases both afterload and preload c. Significantly decreases mortality in Caucasian patients d. Has almost no reported adverse effects 17. Which of the following HF patients would NOT like- an ACE inhibitor can be improved by switching to an ARB? a. b. c. d. Hypotension Cough Hyperkalemia Renal insufficiency ly benefit from warfarin anticoagulation therapy? a. b. c. d. EF <40% Concomitant atrial fibrillation Patient with mechanical valves LV thrombus on echocardiogram 11. The following B-blockers are currently recom- mended for use in HF based on clinical trials EXCEPT: a. b. c. d. Metoprolol tartrate Metoprolol succinate Carvedilol Bisoprolol 18. Lifestyle modifications for HF patients include which of the following? a. b. c. d. Exercise restriction to avoid stressing the heart Aggressive fluid restriction Limited use of salt substitutes Sodium restriction of <500 mg/day http://www.drugtopics.com

Table of Contents Feed for the Digital Edition of Drug Topics - June 16, 2008

Drug Topics - June 16, 2008 Contents Latebreakers Letters Latebreakers in Depth Pharmacists Lose in Final ESRD Rule New Drug Helps Palliative Patients on Opioids Take Care of Business Oral Treatment Reduces Multiple Sclerosis Flare-ups Beware of Inflammatory Masses From Implantable Infusion Systems Safer Therapeutic Options Emerging for Atrial Fibrillation Congressional Committee Chair Calls for Action Against Hospital Infections This Software System Helps Hospitals Manage Anticoagulation Therapy Rx Care Community Practice JP at Large Self-Care Cover Story Long-Term Care Chains and Business Technology Technology Update Continuing Education New Products Advertisers Index Classified Viewpoint

Drug Topics - June 16, 2008

For optimal viewing of this digital publication, please enable JavaScript and then refresh the page. If you would like to try to load the digital publication without using Flash Player detection, please click here.